Constipation in Older Adults - Bowel Regimen and Opioid Induced Constipation

Key Points

• New or severe constipation requires assessment for obstruction, impaction, and secondary causes.
• Overflow diarrhea can be a sign of fecal impaction.
• Polyethylene glycol and stimulant laxatives are effective core therapies for many older adults.
• Start prophylactic bowel therapy with regular opioid use unless contraindicated.
• Docusate alone is often inadequate for established or opioid-induced constipation.
• Bulk fiber can worsen symptoms when fluid intake is poor or obstruction is possible.
• PAMORAs are options for refractory opioid-induced constipation after routine laxatives.
• Medication review and mobility are part of treatment, not optional extras.

Algorithm

1. Assess bowel pattern, red flags, medications, fluid intake, mobility, and abdominal findings.
2. Perform rectal examination when impaction is suspected.
3. If obstruction or acute abdomen is possible, obtain urgent imaging and surgical evaluation as appropriate.
4. Treat impaction before relying on maintenance therapy.
5. Start or optimize an osmotic and/or stimulant bowel regimen.
6. For opioid-induced constipation, ensure prophylaxis and consider a PAMORA if refractory and obstruction is excluded.
7. Address hydration, activity, toileting, and constipating medications.
8. Reassess when symptoms change or red flags develop.

Clinical Synopsis & Reasoning

Constipation should be defined by the patient's change from baseline and symptoms, not a universal requirement for daily bowel movements. Ask about stool frequency and form, straining, sensation of incomplete evacuation, manual maneuvers, abdominal pain, vomiting, blood, weight loss, medication changes, mobility, fluid intake, and prior colorectal disease. In older adults, new severe constipation can reflect dehydration, hypothyroidism, hypercalcemia, neurologic disease, colorectal cancer, or medications such as opioids, anticholinergics, iron, calcium-channel blockers, and aluminum-containing antacids.

Red flags include peritoneal signs, persistent vomiting, marked distention, inability to pass flatus, fever, unexplained anemia, gastrointestinal bleeding, significant weight loss, or abrupt onset in a high-risk patient. These findings should prompt evaluation for obstruction, volvulus, malignancy, ischemia, or another acute abdominal process. A rectal examination is useful when impaction is suspected and can identify hard stool, mass, blood, or altered sphincter tone. Overflow diarrhea can occur around an impaction and should not be mistaken for resolution.

Opioid-induced constipation is mechanistically different from simple low-fiber constipation because mu-receptor stimulation reduces intestinal secretion and motility. Tolerance to this effect is limited, so prophylaxis should begin when a regular opioid is started unless diarrhea or another contraindication is present. In a frail patient with poor oral intake, simply adding large amounts of bulk fiber without adequate fluid can worsen bloating or impaction.

Treatment Strategy & Disposition

Treat fecal impaction first when present, using rectal measures, oral osmotic therapy, or manual disimpaction as clinically appropriate. For chronic uncomplicated constipation, polyethylene glycol is a well-tolerated osmotic option. Stimulant laxatives such as senna or bisacodyl are useful when colonic motility is reduced and are commonly paired with opioid therapy. Docusate has limited evidence as monotherapy for established constipation and should not displace more effective agents. Lactulose is effective but can produce gas and bloating. Magnesium-containing products require caution in significant kidney disease.

For opioid-induced constipation that persists despite an adequate stimulant plus osmotic regimen, peripherally acting mu-opioid receptor antagonists such as naloxegol, naldemedine, or methylnaltrexone may be considered when bowel obstruction is not suspected. These agents reverse peripheral opioid effects without intentionally reversing central analgesia, although abdominal pain and diarrhea can occur. Lubiprostone is another option in selected chronic constipation or OIC settings.

Long-term care includes regular toileting opportunities, mobility, adequate fluid and dietary fiber when safe, and review of constipating medications. Set a bowel goal based on comfort and stool consistency rather than a rigid daily target. Escalate evaluation when a previously stable regimen stops working, symptoms become painful or obstructive, bleeding appears, or the patient loses weight. In palliative care, prevention is especially important because constipation can substantially worsen nausea, pain, agitation, and appetite.

Epidemiology / Risk Factors

• Constipation prevalence rises with age, immobility, institutionalization, neurologic disease, and medication burden.
• Opioid-induced constipation is common and often persists for the duration of opioid therapy.
• Fecal impaction is more common in frail, immobile, and cognitively impaired adults.
• Constipation is a frequent preventable cause of discomfort and acute-care use.

Investigations

When to Escalate

Pharmacology

Prognosis / Complications

• Most functional constipation improves with a consistent individualized regimen.
• Untreated impaction can cause urinary retention, delirium, pressure injury, ulceration, or perforation.
• Recurrent symptoms usually signal inadequate maintenance, persistent medication exposure, or an unrecognized secondary cause.
• Quality of life improves when treatment reduces both stool difficulty and regimen burden.

Patient Education / Counseling

• Normalize variation in bowel frequency while focusing on comfort and stool consistency.
• Encourage adequate fluid and activity within cardiac, renal, and mobility limits.
• Explain that opioid constipation usually needs preventive medication from the start.
• Teach patients when rectal bleeding, vomiting, severe pain, or inability to pass gas requires urgent care.
• Provide a written step-up bowel plan for patients or caregivers managing chronic symptoms.

Notes

A bowel regimen should be proactive and titratable. Many older adults cycle between undertreatment and rescue interventions because no one defines a maintenance plan. Document the intended daily or every-other-day strategy, what to do if stools become loose, and when to escalate. In patients receiving chronic opioids, consider bowel prophylaxis part of the opioid prescription itself.

References

1. American Geriatrics Society: 2023 AGS Beers Criteria — Link
2. American Geriatrics Society: Guidelines and Recommendations — Link